At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 110 enrolled
Drug / intervention
Omega-3 Polyunsaturated Fatty Acid +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Tachikawa Project for Prevention of Posttraumatic Stress Disorder With Polyunsaturated Fatty Acid (TPOP): TPOP-02 Study
In Brief
A Phase 3 clinical trial evaluating Omega-3 Polyunsaturated Fatty Acid and Placebo for Trauma and Posttraumatic Stress Disorder. Completed, enrolled 110 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate efficacy and safety of Polyunsaturated Fatty Acid for the prevention of Posttraumatic Stress Disorder (PTSD) in patients with accidental injuries.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTrauma, Posttraumatic Stress Disorder
CountriesJapan
CollaboratorsUniversity of Toyama, Chiba University
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 2008
Enrollment StartDec 2008
Primary CompletionAug 2013
Study CompletionDec 2013
TodayJul 2026
First PostedMay 5, 2008
Enrollment StartDec 1, 2008
Primary CompletionAug 1, 2013
Study CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 18.2 years ago
Interventions
Omega-3 Polyunsaturated Fatty Aciddietary
A capsule of omega-3 Polyunsaturated Fatty Acid, 300mg (including 70% docosahexaenoic acid, 7% eicosapentaenoic acid and other), 7 capsules per day in 12 week.
Placebodietary
Placebo